Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment

Archives of Ophthalmology

Volumn 128, Issue 8, 2010, Pages 1080-1081

  Hoang, Quan V ^a   Kiernan, Daniel F ^a   Chau, Felix Y ^a   Shapiro, Michael J ^a,b   Blair, Michael P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Retina Consultants Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

CASE REPORT; CLINICAL EXAMINATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INFANT; LASER COAGULATION; LETTER; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROLENTAL FIBROPLASIA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FLUORESCEIN ANGIOGRAPHY; GESTATIONAL AGE; HUMANS; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INJECTIONS; LASER COAGULATION; MALE; RECURRENCE; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77955443049     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.145     Document Type: Letter

References (8)

1. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684-1694.
2. Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr. 2009;21(2):182-187.
3. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II [published correction appears in Retina. 2008;28(9):1374]. Retina. 2008; 28(6):831-838.
4. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity [published correction appears in Retina. 2009;29(1):127]. Retina. 2008;28(3)(suppl):S19-S25.
5. Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chévez-Barrios P. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol. 2008; 126(8):1161-1163.
6. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008; 246(7):1061-1063.
7. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10(2):133-140.
8. Stone J, Chan-Ling T, Pe'er J, Itin A, Gnessin H, Keshet E. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1996;37(2):290-299.